In addition, there are no prospective trials comparing different cancer risk–reducing strategies in patients with breast cancer that tested positive for the BRCA1 and BRCA2 pathogenic variants who were treated with BCT at the first event. The gene discussed is BRCA2; the disease is breast cancer.